Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced the grant of inducement awards to five new employees, comprising non-qualified stock options for 29,063 shares. The options have an exercise price of $18.50 per share, equivalent to the closing stock price on June 18, 2021. Vesting occurs as 25% becomes exercisable after one year, with the remaining 75% vesting monthly over three years, contingent on continued employment. Marinus focuses on innovative treatments for seizure disorders, including ongoing clinical trials for ganaxolone, a therapeutic agent for various seizure conditions.

Positive

• Grant of non-qualified stock options to new employees, promoting talent acquisition.
• Stock options priced at $18.50 per share, matching the recent closing price, suggesting alignment with market value.

Negative

• None.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 29,063 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

These stock option grants have an exercise price of $18.50 per share, which is equal to the closing price of the Common Stock on June 18, 2021 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee’s start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments at the end of each month following such anniversary, subject to the applicable employee’s continued employment with Marinus on such vesting dates. The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex and has recently disclosed top-line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005845/en/

FAQ

What recent announcement did Marinus Pharmaceuticals make regarding employee compensation?

Marinus Pharmaceuticals announced the grant of inducement stock options to five new employees, totaling 29,063 shares.

What is the exercise price for the stock options granted by Marinus Pharmaceuticals?

The exercise price for the stock options is $18.50 per share, equal to the closing price on June 18, 2021.

How will the stock options granted by Marinus Pharmaceuticals vest?

The stock options will vest 25% on the one-year anniversary of employment, with the remaining 75% vesting in equal monthly installments over three years.

What is the focus of Marinus Pharmaceuticals' clinical development?

Marinus Pharmaceuticals is focused on developing innovative therapeutics for treating seizure disorders, including ongoing trials for ganaxolone.